CTRI/2022/03/041208尚未招募未知
Comparison of Efficacy & Safety of Dasatinib versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia with Reference to Early Molecular Response An Exploratory Study
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Study Population: Newly diagnosed chronic phase chronic myeloid leukemia patients who fulfil inclusion criteria will be enrolled in the study.
- •Inclusion Criteria:
- •Newly diagnosed patients with chronic phase CML.
- •Age >= 12 years, both males & females.
- •Patients willing to provide written informed consent.
排除标准
- •Exclusion Criteria:
- •Patients with de novo accelerated phase or blast phase CML.
- •Patients who have already started any tyrosine kinase inhibitor (TKI) treatment prior to randomization (Hydroxyurea started for initial cytoreduction is permitted).
- •Pregnancy.
- •Lactation.
- •Patients with pre-existing pleural effusion, grade >= 3 lung disease, or pulmonary arterial hypertension.
- •Patients with angina, or grade >= 3 cardiac disease[as defined by the New York Heart Association (NYHA) criteria] at diagnosis.
- •Patients with prolonged QTc interval ( > 480 msec) at baseline, or taking any concomitant medication known to prolong QTc interval.
研究者
相似试验
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-GBEBMT (European group for Blood and Marrow Transplantation)50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow TransplantatioEUCTR2008-001361-29-FREBMT (European group for Blood and Marrow Transplantation)50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-DEEBMT (European group for Blood and Marrow Transplantation)50
已完成
2 期
Phase II Study of Safety and Efficacy. Dasatinib in Patients with Chronic Phase Chronic Myelogenous Leukemia achieving a Major Molecular Response on Imatinib.Chronic phase chronic myelogenous leukemiaJPRN-UMIN000007413CML stem cell study group20
招募中
不适用
In-vivo Bioequivalence Test of Dasatinib tablets with brand drug (SPRYCEL® 140 mg, Rosche, Switzerlandd)Plasma drug concentration.IRCT20200105046010N56anoalvand Pharmaceutical Co24